Supplementary Figure S7 from BCL2 Inhibition Reveals a Dendritic Cell–Specific Immune Checkpoint That Controls Tumor Immunosurveillance

<p>Supplementary Figure S7 shows the activation of human peripheral cDC1 cells by BCL2 inhibitors, as well as the in vivo migration of adoptively transferred cDC1 cells that were either WT, BCL2 inhibitor-treated or Bcl2 knock out.</p>